Welcome to our dedicated page for NewGenIvf Group SEC filings (Ticker: NIVF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NewGenIvf Group Limited (NIVF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. NewGenIvf files reports with the U.S. Securities and Exchange Commission primarily on Form 20-F and Form 6-K, detailing its evolving business across fertility services, technology licensing, digital assets, and real estate development.
Investors can review Form 6-K current reports that furnish unaudited interim financial results, describe changes to the company’s capital structure, and attach key press releases. Recent 6-Ks have covered multiple reverse stock splits, increases in authorized share capital, and updates on issued and outstanding shares. These filings explain how reverse splits affect the number of Class A ordinary shares and the adjustment of options, warrants, and convertible securities.
Other 6-K submissions include exhibits for announcements such as the share repurchase program, joint venture and joint development arrangements in Ras Al Khaimah, digital asset and tokenization agreements, and the non-binding term sheet for a proposed reverse merger with SAXA, Inc. Together, these documents outline NewGenIvf’s diversification into technology-driven fertility solutions, digital asset strategies, and UAE real estate projects.
On Stock Titan, each NIVF filing is paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand items like capital changes, financing agreements, and strategic transactions. Users can monitor new 6-Ks as they are posted to EDGAR, and refer to annual 20-F reports for a more comprehensive view of NewGenIvf’s business description, risk factors, and financial statements.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every three existing shares. This affects Class A ordinary shares, Class B ordinary shares and preferred shares and was approved by the board under BVI law without a shareholder vote.
The reverse split will be effective at 12:01 a.m. (ET) on January 26, 2026, with Class A ordinary shares beginning Nasdaq trading on a split-adjusted basis the same day under the symbol NIVF and a new CUSIP. The number of outstanding Class A ordinary shares will change from 2,948,080 to approximately 982,694, with every three pre-split shares automatically becoming one post-split share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one full share. Outstanding options, warrants and other convertible securities will be adjusted by dividing the underlying share amounts by three.
NewGenIvf Group Limited is implementing a one-for-five reverse stock split of its issued and unissued Class A Ordinary Shares. The reverse split will be effective at 12:01 a.m. (ET) on December 1, 2025, and the shares will begin trading on a split-adjusted basis on Nasdaq the same day under the existing ticker NIVF.
The reverse split will reduce the number of outstanding Class A Ordinary Shares from 6,585,672 to approximately 1,317,135, so every five existing shares will be combined into one new share. No fractional shares will be issued; any shareholder who would otherwise receive a fraction will receive one whole post-split share instead. All outstanding options, warrants and other convertible securities will be adjusted by dividing the underlying share amount by five, rounded to the nearest whole share.
NewGenIvf Group Limited approved a 1‑for‑5 reverse stock split to support compliance with Nasdaq’s minimum
The action will reduce outstanding Class A Ordinary Shares from approximately 4,844,490 to approximately 968,898. Every five pre‑split Class A shares will automatically combine into one post‑split share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole post‑split share at the participant level. Outstanding options, warrants and other convertibles will be adjusted by dividing the underlying share counts by five. No shareholder vote is required under BVI law, par value remains nil, and the authorized share amount is unlimited and unaffected.
NewGenIvf Group Limited announced a share repurchase program of up to US$2 million, as indicated in Exhibit 99.1 to a Form 6-K filing. Share repurchases can support shareholder value by decreasing the number of shares available in the market over time. The filing lists the program amount but does not include additional terms in this excerpt.
NewGenIvf Group Limited (NIVF) furnished a Form 6-K reporting that NewGenDigital has been appointed as SAXA Inc.’s agent for the tokenization of US$100 million of gold-backed assets. The filing lists this appointment under an accompanying company announcement.
The report was signed by the company’s Chairman, Wing Fung Alfred Siu, on November 5, 2025. No additional financial results or operating metrics are included in this submission beyond the appointment and the stated asset value.
NewGenIvf Group Limited filed a prospectus to register the resale of up to 50,000,000 Class A Ordinary Shares by selling securityholders. This includes 20,000,000 shares issuable to White Lion under a Common Stock Purchase Agreement and 30,000,000 shares issuable to JAK Opportunities VI LLC upon conversion of notes and exercise of warrants.
The company is not selling securities in this offering and will not receive proceeds from resales. Separately, it may receive up to $500,000,000 from sales of newly issued shares to White Lion under the purchase agreement, subject to its terms. The agreement includes a 4.99% beneficial ownership cap (at White Lion’s discretion, up to 9.99%).
As context, shares outstanding were 2,952,702 as of October 31, 2025. The company effected a 1-for-20 reverse stock split on February 11, 2025 and subsequently regained compliance with Nasdaq’s minimum bid price rule; its shares trade on Nasdaq Capital Market under NIVF.
NewGenIvf Group Limited filed a Form 6-K as a foreign private issuer to furnish its unaudited financial results for the six months ended June 30, 2025. These interim results are provided as an exhibit to the report rather than being fully detailed in the body of the filing.
The company notes that the financial information is unaudited and may be adjusted when year-end audit procedures are performed, which could lead to significant differences from the numbers currently presented in the interim results.
FAQ
What is the current stock price of NewGenIvf Group (NIVF)?
What is the market cap of NewGenIvf Group (NIVF)?
